2024
-
Celebrate 5 Decades of the World Conference on Lung Cancer in San Diego’s Historic Gaslamp Quarter
Come dressed in the style of your favorite decade from the ‘70s to today when you join your colleagues for an unforgettable block party to honor 50 years of progress in lung cancer.
-
2024 IASLC Academy to Once Again Compete in Amazing Case Race
After a successful inaugural year in 2023, participants have once again crafted case summaries, and WCLC 2024 attendees will help choose the winning cases.
-
Get Moving and Win During the 2024 Wellness Challenge
Stay active during your time in San Diego by taking part in IASLC’S Wellness Challenge, Step It Up for Research.
-
Know Before You Go: What You Need to Know to Get to—and Navigate—San Diego
With the 2024 World Conference on Lung Cancer less than a month away, now is the time to make sure you know where you’re headed and how to get there.
-
Gender Disparity in Lung Cancer
Drs. Jyoti Patel and Khyati Somayaji Dasika say the increased burden of lung cancer on women underscores the necessity for gender-sensitive approaches in healthcare policy, research, and clinical practice.
-
BEAT-meso Trial Again Identifies Non-epithelioid Mesothelioma as Distinct Population
While the study did not meet its primary endpoint of overall survival, it did demonstrate a significant benefit in overall and progression-free survival in the non-epithelioid patient population.
-
Concurrent IO with Chemoradiotherapy: Insights from PACIFIC-2
In an interview with ILCN, principal investigator Dr. Jeffrey Bradley discusses his thoughts on why the trial proved negative.
-
Big Tobacco Targets Medical Education
In a commentary, Drs. Deepti Behl and Carolyn Dresler highlight the tobacco industry’s recent efforts to influence healthcare providers under the guise of smoking cessation education.
-
FLAURA-2 Results Lead to Approval of Osimertinib Plus Chemotherapy in European Union, Japan
In other recent regulatory news, Health Canada authorized amivantamab in combination with carboplatin and pemetrexed for patients with non-small cell lung cancer with EGFR Exon 20 insertion mutations.
-
Patient Advocate Ivy B. Elkins Leaves Lasting Legacy
Ms. Elkins, co-founder of the EGFR Resisters advocacy group, will be remembered for her warm and energetic approach to furthering lung cancer research efforts.
View ILCN Archives
Provider Resources